TuHURA Biosciences financials
$2.07−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — |
| Operating income | -$8.8M | -$7.5M | -$8.2M | -$6.7M | -$9.9M | -$7.0M | -$5.7M |
| Net income | -$9.2M | -$7.5M | -$6.8M | -$7.1M | -$9.5M | -$6.7M | -$6.0M |
| Net margin | — | — | — | — | — | — | — |
| Diluted EPS | $-0.14 | $-0.13 | $-0.13 | $-0.14 | $-0.21 | $-0.15 | $-0.16 |
| EBITDA | -$8.7M | -$7.5M | -$4.5M | -$6.7M | -$6.8M | -$6.6M | -$5.2M |
| Operating cash flow | -$8.6M | -$4.4M | -$5.6M | -$11.1M | -$6.2M | -$4.7M | -$2.6M |
| Free cash flow | -$8.8M | -$4.5M | -$5.6M | -$11.1M | -$6.3M | -$4.8M | -$2.6M |
| Diluted shares | 64.0M | 60.0M | 53.1M | 50.7M | 44.6M | 43.4M | 38.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $996.0K | $6.3M | $3.6M | $2.7M | $8.5M | $6.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $5.2M | $0.00 | $0.00 | $493.4K | $434.0K | $0.00 |
| Total assets | $31.7M | $29.7M | $27.4M | $25.7M | $34.6M | $14.6M |
| Total liabilities | $13.2M | $6.5M | $6.4M | $8.9M | $15.2M | $1.7M |
| Shareholders' equity | $18.5M | $23.2M | $20.9M | $16.8M | $19.4M | $12.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology